Could a transplant drug slow a rare muscle disease?

NCT ID NCT04789070

First seen Jan 19, 2026 · Last updated May 15, 2026 · Updated 15 times

Summary

This phase 3 trial tests sirolimus, a drug used in organ transplants, to see if it can slow or stop muscle decline in people with inclusion body myositis (IBM), a rare muscle disease. About 140 adults aged 45 and older who can walk at least 200 meters are taking part. The study measures changes in daily function and walking ability over 84 weeks.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INCLUSION BODY MYOSITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Austin Health

    Melbourne, Victoria, Australia

  • Concord Repatriation Hospital

    Sydney, New South Wales, Australia

  • Johns Hopkins University

    Baltimore, Maryland, 21218, United States

  • Leiden University Medical Center

    Leiden, Netherlands

  • Perron Institute

    Perth, Washington, Australia

  • Royal Adelaide Hospital

    Adelaide, South Australia, Australia

  • Royal Brisbane and Women's Hospital

    Brisbane, Queensland, Australia

  • Royal Northshore Hospital

    Sydney, New South Wales, Australia

  • St Vincent's Hospital

    Melbourne, Victoria, Australia

  • University of Kansas Medical Center

    Kansas City, Kansas, 66160, United States

Conditions

Explore the condition pages connected to this study.